SCHEMBL31127858

SCHEMBL31127858

CCc1c(Cl)cc2c(cnn2C2CCCCO2)c1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.41
▸ RXRB P28702 1/20 0.41
▸ RXRG P48443 1/20 0.41
▸ CYP4F2 P78329 2/20 0.36
▸ CYP4A11 Q02928 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ PDE4D Q08499 1/20 0.35
▸ DGAT2 Q96PD7 1/20 0.34
▸ RET P07949 2/20 0.34
▸ PDE1A P54750 4/20 0.33
▸ PDE1B Q01064 4/20 0.33
▸ PDE1C Q14123 4/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33
▸ ATR Q13535 4/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ P2RY12 Q9H244 1/20 0.32
▸ PDE9A O76083 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923121 0.90 RXRA (0.42) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31642674 0.89 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31642955 0.89 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922966 0.88 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922456 0.88 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922816 0.87 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31041020 0.87 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31040997 0.86 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922777 0.86 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922464 0.86 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688788-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS Pfizer Inc. (US) 2026-02-11 — — EP disclosed
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds PFIZER INC. (US) 2025-04-22 — — US disclosed
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2025-01-30 — — US disclosed
WO-2024209339-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-10-10 — — WO disclosed
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds PFIZER INC. (US) 2024-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds DPYD, PNPO, TYMP RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds DPYD, PNPO, TYMP RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS DPYD, PNPO, TYMP RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback